Loading stock data…
Stereotaxis, Inc. (STXS)
$1.30-0.09 (-6.47%)
Market ClosedLast close Sep 8
Stereotaxis, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stereotaxis, Inc. in the Healthcare sector is trading at $1.30 with a market capitalization of $180M. Wall Street consensus targets $3.00 (3 analysts), implying a +130.8% move over the next 12 months. The stock is currently near its 52-week low of $1.24, remaining 33.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +130.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.29M↓ | $8.64M↑ | $7.46M↓ | $8.80M↑ | $7.47M |
| Gross Profit | $3.79M↓ | $4.33M↑ | $4.10M↓ | $4.58M↑ | $4.06M |
| Operating Income | -$5.98M↓ | -$5.65M↑ | -$6.56M↓ | -$3.98M↑ | -$5.93M |
| Net Income | -$5.86M↓ | -$5.53M↑ | -$6.46M↓ | -$3.83M↑ | -$5.82M |
Peer Comparison
JNJUNHPFE
Fundamentals
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$179.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-110.63%
Volume
Today's trading volume
724,573
Recent News
Stereotaxis (STXS) Q2 2026 Earnings Call Transcript
MAGiC catheter adoption accelerates with 12 U.S. sites now performing procedures.
ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?
ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.
Stereotaxis, Inc. Q2 2026 Earnings Call Summary
Moby summary of Stereotaxis, Inc.'s Q2 2026 earnings call
Stereotaxis Q2 Earnings Call Highlights
Stereotaxis (NYSEAMERICAN:STXS) reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints. Revenue declined from the prior-year quarter be
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of -66.67% and -19.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?